Opko Health, Inc. (NASDAQ:OPK)

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It develops a range of solutions, including molecular diagnostics tests, point-of-care tests, and proprietary pharmaceuticals and vaccines to diagnose, treat, and prevent various conditions. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer’s disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; and point-of-care diagnostic test for prostate specific antigen. It is also developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; vaccines using alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate, which has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. In addition, the company offers specialty active pharmaceutical ingredients in Israel; manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products in Mexico; and markets, sells, and distributes cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones in Chile. OPKO Health, Inc. was founded in 2006 and is based in Miami, Florida.